|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/11/19 DelMar Pharmaceuticals, Inc. S-1/A 71:7.9M Edgar Agents LLC/FA |
Document/Exhibit Description Pages Size
1: S-1/A Amendment No. 1 to Form S-1 HTML 1.11M
2: EX-23.1 Consent of Ernst & Young, LLP HTML 19K
9: R1 Document and Entity Information HTML 34K
10: R2 Consolidated Condensed Interim Balance Sheets HTML 90K
11: R3 Consolidated Condensed Interim Balance Sheets HTML 41K
(Parenthetical)
12: R4 Consolidated Condensed Interim Statements of Loss HTML 63K
and Comprehensive Loss
13: R5 Consolidated Statements of Changes in HTML 112K
Stockholders' Equity
14: R6 Consolidated Condensed Interim Statements of Cash HTML 84K
Flows
15: R7 Going Concern, Nature of Operations, and Corporate HTML 40K
History
16: R8 Significant Accounting Policies HTML 81K
17: R9 Valent Technologies, LLC HTML 28K
18: R10 Derivative Liability HTML 61K
19: R11 Stockholders' Equity HTML 227K
20: R12 Financial Instruments HTML 36K
21: R13 Related Party Transactions HTML 22K
22: R14 Current and Deferred Income Taxes HTML 37K
23: R15 Commitments and Contingencies HTML 25K
24: R16 Supplementary Statement of Cash Flows Information HTML 31K
25: R17 Financial Risk Management HTML 34K
26: R18 Subsequent Events HTML 32K
27: R19 Significant Accounting Policies (Policies) HTML 129K
28: R20 Significant Accounting Policies (Tables) HTML 25K
29: R21 Derivative Liability (Tables) HTML 57K
30: R22 Stockholders' Equity (Tables) HTML 202K
31: R23 Financial Instruments (Tables) HTML 28K
32: R24 Current and Deferred Income Taxes (Tables) HTML 47K
33: R25 Supplementary Statement of Cash Flows Information HTML 30K
(Tables)
34: R26 Financial Risk Management (Tables) HTML 33K
35: R27 Going Concern, Nature of Operations, and Corporate HTML 37K
History (Details)
36: R28 Significant Accounting Policies (Details) HTML 30K
37: R29 Significant Accounting Policies (Details Textual) HTML 45K
38: R30 Valent Technologies, LLC (Details) HTML 49K
39: R31 Derivative Liability (Details) HTML 37K
40: R32 Derivative Liability (Details 1) HTML 41K
41: R33 Derivative Liability (Details Textual) HTML 71K
42: R34 Stockholders' Equity (Details) HTML 100K
43: R35 Stockholders' Equity (Details 1) HTML 30K
44: R36 Stockholders' Equity (Details 2) HTML 37K
45: R37 Stockholders' Equity (Details 3) HTML 40K
46: R38 Stockholders' Equity (Details 4) HTML 118K
47: R39 Stockholders' Equity (Details 5) HTML 38K
48: R40 Stockholders' Equity (Details 6) HTML 30K
49: R41 Stockholders' Equity (Details 7) HTML 51K
50: R42 Stockholders' Equity (Details 8) HTML 35K
51: R43 Stockholders' Equity (Details 9) HTML 58K
52: R44 Stockholders' Equity (Details 10) HTML 90K
53: R45 Stockholders' Equity (Details 11) HTML 33K
54: R46 Financial Instruments (Details) HTML 28K
55: R47 Related Party Transactions (Details) HTML 23K
56: R48 Current and Deferred Income Taxes (Details) HTML 47K
57: R49 Current and Deferred Income Taxes (Details 1) HTML 44K
58: R50 Current and Deferred Income Taxes (Details HTML 46K
Textual)
59: R51 Commitments and Contingencies (Details) HTML 27K
60: R52 Stockholders' Equity (Details Textual) HTML 91K
61: R53 Stockholders' Equity (Details Textual 1) HTML 66K
62: R54 Stockholders' Equity (Details Textual 2) HTML 52K
63: R55 Stockholders' Equity (Details Textual 3) HTML 46K
64: R56 Supplementary Statement of Cash Flows Information HTML 43K
(Details)
65: R57 Financial Risk Management (Details) HTML 27K
66: R58 Financial Risk Management (Details 1) HTML 28K
67: R59 Financial Risk Management (Details Textual) HTML 48K
68: R60 Subsequent Events (Details) HTML 51K
70: XML IDEA XML File -- Filing Summary XML 133K
69: EXCEL IDEA Workbook of Financial Reports XLSX 101K
3: EX-101.INS XBRL Instance -- dmpi-20190331 XML 2.20M
5: EX-101.CAL XBRL Calculations -- dmpi-20190331_cal XML 142K
6: EX-101.DEF XBRL Definitions -- dmpi-20190331_def XML 703K
7: EX-101.LAB XBRL Labels -- dmpi-20190331_lab XML 1.14M
8: EX-101.PRE XBRL Presentations -- dmpi-20190331_pre XML 897K
4: EX-101.SCH XBRL Schema -- dmpi-20190331 XSD 211K
71: ZIP XBRL Zipped Folder -- 0001213900-19-012524-xbrl Zip 171K
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption "Experts" and to the use of our report dated September 21, 2018 (except Note 11, as to which the date is May 8, 2019), in Amendment No. 1 to the Registration Statement (Form S-1 No. 333-232332) and related Prospectus of DelMar Pharmaceuticals, Inc. for the registration of up to 760,500 shares of its common stock.
| Vancouver, Canada, | /s/ Ernst & Young LLP |
| July 11, 2019 | Chartered Professional Accountants |
| This ‘S-1/A’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 7/11/19 | CORRESP | ||
| 5/8/19 | 8-K, CORRESP, S-1/A | |||
| 9/21/18 | ||||
| List all Filings | ||||